PubMed Health⌕ Search

Biomedical subjects

T Haba

Publications and source records attributed to T Haba.

At least 37 records · Page 2Linked to original sources
PubMed1991

An immunohistochemical study on the effects of cyclosporin on the gut-associated lymphoid tissue of rats.

The effect of Cyclosporin (CS) on the gut-associated lymphoid tissue (GALT) of inbred WKA rats was immunohistochemically studied by the immunoperoxidase method. CS in olive oil was orally administered daily for seven days at the dose of 25, 50 and 100 mg/kg/day. On days 1, 4 and 7 of CS administration, rats were sacrificed under ether anesthesia. By CS administration, the decrease and disappearance of Ia antigen expression were dose-dependently recognized on the epithelial cells and the overlaying cells of Peyer's patches. The reduced cellular population and Ia expression of lymphocytes of the follicle and the disappearance of the germinal center also occurred, and Ia-positive dendritic non-lymphoid cells in Peyer's patches and endothelial cells of capillaries in the lamina propria disappeared on day 7 of CS administration. In addition, a temporary increase of W3/25-positive cells and the appearance of Ia-positive intra-epithelial cells were observed on day 4. Simultaneously, interleukin 2 receptor (IL-2R)-positive cells gradually decreased on day 4, and almost disappeared on day 7. From these results, it is speculated that CS suppresses not only interleukin 2 (IL-2) production as previously reported, but also the expression of Ia antigens and IL-2R. It may well suppress the immune system at the point of recognition and presentation of alloantigen, and the proliferation and differentiation of B cells.

Animals↗
PubMed1989

[Studies on drug release from anti-cancer drug suspended Lipiodol].

In case of an arterial infusion chemoembolization therapy for primary or metastatic liver cancer, gradual release of the anti-cancer drug from lipiodol is a very important factor for a higher drug concentration in the tumor and for longer contact. We studied basic points about what kind of drug form has a gradual drug release. We prepared 3 forms of drugs. (1) Powder form: Powder of ADM, MMC and CDDP was suspended in lipiodol with ultrasonic suspender. (2) URO form: ADM and MMC were dissolved with Urografin and mixed with lipiodol. (3) Surfactant form: ADM and MMC were dissolved with water and then mixed with lipiodol using surfactant. We put lipiodol suspension into physiological saline and then stirred water at 100 rpm with the paddle method, measuring drug release from the suspension or emulsion. Powder form had a lowest drug release. In clinical trials, we administered intra-arterially (1) ADM, MMC dissolved with physiological saline water as usually used (physiological saline water form) (2) Powder form; (3) URO from; (1) CDDP solution as usually used was administered; (2) Powder form. Then we studied the changes of serum concentration of ADM, MMC and CDDP. The results indicated that powder form had the lowest drug release. Thus, the water-soluble anti-cancer drugs ADM, MMC and CDDP should be used in powder form.

Antineoplastic Agents↗
PubMed1988

Decreased serum cholesteryl-ester transfer activity in a patient with familial hyperalphalipoproteinemia.

Lipoprotein patterns and cholesteryl-ester transfer activity (CETA) were examined in a patient with familial hyperalphalipoproteinemia (FHALP). The proband was a 41-year-old Japanese male. He was found to have hypercholesterolemia, with a serum total cholesterol level of 382 mg/dl and a HDL-cholesterol level of 177 mg/dl. HDL showed a high cholesterol/Apo AI ratio. His father, all of his siblings and one of his children showed high HDL-cholesterol levels (91, 100, 70, 108, 75 and 98 mg/dl, respectively). These data suggest that all members of his family were heterozygotes. He had neither cutaneous or tendinous xanthomas nor any clinical signs of atherosclerosis. The proband appears to have only one-tenth of the normal level of CETA. However, the level of lipid-transfer protein I (LTP-I) activity was near normal. Thus, this patient is most likely to have an exaggerated level of LTP-I inhibitor(s). Effects of probucol on serum lipoprotein and apolipoprotein levels were studied in our patient. Treatment with 250 mg of probucol twice daily reduced total serum cholesterol, low density lipoprotein (LDL) and HDL-cholesterol levels by 33.32 and 33%, respectively. Apo AI, B and E levels decreased by 22, 16 and 35% respectively. HDL-cholesterol/Apo AI ratio decreased from 0.9 to 0.76. CETA showed no significant changes. However, cholesterol ester mass transfer increased from 10.8 to 14.9% after treatment with probucol. These results suggest that probucol appears to be a useful drug for FHALP.

Adolescent↗
PubMed1988

[Arterial infusion of anticancer agent and lipiodol using a totally implanted drug delivery system].

We attempted arterial infusion of anticancer agent using a totally implanted drug delivery system in 52 patients who had inoperable liver cancer or the scheduled adjuvant chemotherapy after hepatic resection. The response rate of the cases using lipiodol was 38%, while that of the cases using only ADM and MMC was 0%. We studied changes in serum concentration of ADM and MMC. The results indicated that using 60% Urographin to make ADM, MMC-lipiodol emulsion was effective for targetting and control release.

Antineoplastic Combined Chemotherapy Protocols↗